Skip to Content

Tlando Approval Status

  • FDA approved: No
  • Brand name: Tlando
  • Generic name: testosterone
  • Previous name: LPCN 1021
  • Company: Lipocine Inc.
  • Treatment for: Hypogonadism, Male

Tlando (testosterone) is an oral testosterone replacement therapy in development for the treatment of males with conditions associated with a deficiency or absence of endogenous testosterone, also known as hypogonadism.

Development Status and FDA Approval Process for Tlando

Aug 14, 2017Lipocine Announces FDA Acknowledgement of Tlando (LPCN 1021) NDA Resubmission
Aug  9, 2017Lipocine Resubmits NDA for Its Oral Testosterone Product Candidate, LPCN 1021, for Treatment of Hypogonadism
Jun 29, 2016Lipocine Receives Complete Response Letter (CRL) for LPCN 1021 From U.S. FDA
Nov 12, 2015Lipocine Announces PDUFA Goal Date for LPCN 1021 NDA
Oct 29, 2015FDA Accepts for Filing Lipocine's NDA for Its Oral Testosterone Replacement Product Candidate, LPCN 1021
Aug 31, 2015Lipocine Submits NDA to FDA for Its Oral Testosterone Replacement Product Candidate, LPCN 1021

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.